Zentalis doses first patient in Phase 3 ASPENOVA ovarian cancer trial
Zentalis Pharmaceuticals has dosed the first patient in ASPENOVA, a global Phase 3 randomised controlled trial of its investigational WEE1 inhibitor azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The milestone, announced on 5 May 2026, marks a pivotal step in Zentalis' dual-track regulatory strategy, which pairs ASPENOVA against an ongoing Phase 2 registration study called DENALI, the latter expected to yield topline results by the end of this year.
ASPENOVA is designed to enrol approximately 420 patients across sites operated in collaboration with The GOG Foundation, the European Network of Gynaecological Oncological Trial groups (ENGOT), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT). Participants are randomised to azenosertib monotherapy at 400mg once daily on a 5-days-on, 2-days-off schedule, or to investigator's choice of standard-of-care single-agent chemotherapy — paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan. The primary endpoint is progression-free survival, with overall survival and overall response rate as key secondary endpoints.
The dual-track regulatory strategy
Zentalis is simultaneously pursuing accelerated approval via the DENALI Phase 2 trial, which is prospectively enrolling Cyclin E1-overexpressing PROC patients. DENALI Part 2a confirmed 400mg QD 5:2 as the optimal dose following an April 2026 interim analysis showing a clearly differentiated response rate over the 300mg dose level at a comparable safety profile. Enrolment expansion cohorts — Parts 2b and 2c — are currently recruiting, with a full topline readout targeted before year-end 2026. If that readout supports an accelerated approval submission, ASPENOVA would serve as the confirmatory study required by the FDA for conversion to full approval. The trial design was reportedly aligned with the agency in advance.
Ingmar Bruns, chief medical officer at Zentalis, said the company is "executing on a comprehensive development and regulatory strategy designed to bring this therapy to patients as quickly as possible." Fiona Simpkins, professor at the University of Pennsylvania Perelman School of Medicine and lead investigator for ASPENOVA, noted that Cyclin E1 overexpression has yet to be exploited therapeutically, and described azenosertib as "an oral, targeted treatment that is showing exciting activity" in this biomarker-selected population.
Azenosertib holds FDA Fast Track Designation for Cyclin E1-positive PROC. The company says Cyclin E1 overexpression accounts for approximately 50% of PROC patients, a group with no currently approved biomarker-specific treatment option.
Market context and competitive landscape
Platinum-resistant ovarian cancer represents one of the most clinically challenging segments of gynaecological oncology. Standard salvage regimens produce modest response rates, and no targeted agent has yet achieved full approval in a prospectively biomarker-selected PROC population. WEE1 inhibition as a therapeutic strategy has attracted significant interest given the role of the WEE1 kinase in regulating G2-M cell cycle checkpoints; cancer cells with high replicative stress — a hallmark of Cyclin E1 amplification — are theoretically more vulnerable to checkpoint abrogation.
Zentalis is not the only company in this space: several other clinical-stage programmes are exploring cell cycle checkpoint inhibitors and DNA damage response agents in ovarian cancer, though none have yet achieved approval in a directly comparable biomarker-stratified population. The DENALI readout at the end of 2026 will be a critical data inflection point, not only for Zentalis' accelerated approval pathway but as a signal for the broader WEE1 inhibitor field. Investors and oncology specialists will be watching closely for response rate data and the safety profile at the 400mg dose, particularly any haematological or gastrointestinal toxicities that have historically complicated WEE1 inhibitor development across the class.